Linagliptin as add-on treatment to glimepiride in patients with HNF1A-diabetes (MODY3): a randomised, double-blinded, placebo-controlled, crossover trial

A. S. Christensen, S. Haedersdal, J. Stoy, H. Storgaard, U. Kampmann, M. Seghieri, J. J. Holst, T. Hansen, F. K. Knop, T. Vilsboll

OriginalsprogEngelsk
Publikationsdatosep. 2020
StatusUdgivet - sep. 2020

Citationsformater